4//SEC Filing
Abeliovich Asa 4
Accession 0001209191-20-065696
CIK 0001714798other
Filed
Dec 30, 7:00 PM ET
Accepted
Dec 31, 4:54 PM ET
Size
12.9 KB
Accession
0001209191-20-065696
Insider Transaction Report
Form 4
Abeliovich Asa
DirectorPresident & CEO10% Owner
Transactions
- Exercise/Conversion
Common Stock
2020-12-30$10.26/sh+120,537$1,236,710→ 2,474,793 total - Exercise/Conversion
Stock Option (Right to Buy)
2020-12-30−5,256→ 1,329,219 totalExercise: $0.18Exp: 2028-03-05→ Common Stock (5,256 underlying) - Exercise/Conversion
Stock Option (Right to Buy)
2020-12-30−120,537→ 178,681 totalExercise: $10.26Exp: 2029-04-24→ Common Stock (120,537 underlying) - Exercise/Conversion
Common Stock
2020-12-30$0.18/sh+5,256$946→ 2,354,256 total - Tax Payment
Common Stock
2020-12-30$23.02/sh−89,037$2,049,632→ 2,385,756 total
Footnotes (2)
- [F1]25% of the total number of shares underlying the option vested and became exercisable on March 7, 2019 and an additional 1/48th of the total number of shares underlying the option shall vest and become exercisable on the first day of each of the thirty-six (36) consecutive months thereafter subject, in all cases, to the Reporting Person providing continuous service with the Issuer on each such date.
- [F2]25% of the total number of shares underlying the option shall vest and become exercisable on April 24, 2020 and an additional 1/48th of the total number of shares underlying the option shall vest and become exercisable on the same date of each of the thirty-six (36) consecutive months thereafter subject, in all cases, to the Reporting Person providing continuous service with the Issuer on each such date.
Documents
Issuer
Prevail Therapeutics Inc.
CIK 0001714798
Entity typeother
Related Parties
1- filerCIK 0001778476
Filing Metadata
- Form type
- 4
- Filed
- Dec 30, 7:00 PM ET
- Accepted
- Dec 31, 4:54 PM ET
- Size
- 12.9 KB